FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017144533> ?p ?o ?g. }

• W2017144533 endingPage "5125" @default.
• W2017144533 startingPage "5119" @default.
• W2017144533 abstract "Abstract Relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) remains a clinical challenge, with limited effective treatment options available after stem cell transplantation. In a multicenter phase 2 study, the efficacy of lenalidomide in rel/ref cHL patients was evaluated at a dose of 25 mg/d on days 1-21 of a 28-day cycle. Patients remained on lenalidomide until disease progression or an unacceptable adverse event (AE) occurred. Thirty-eight cHL patients were enrolled with a median of 4 (range, 2-9) prior therapies; 87% had undergone prior stem cell transplantation and 55% of patients did not respond to their last prior therapy. Of 36 evaluable patients, responses were 1 complete remission (CR), 6 partial remissions (PRs), and 5 patients with stable disease (SD) for ≥ 6 months resulting in an International Working Committee (IWC) objective overall response rate (ORR) of 19% and a cytostatic ORR of 33%. Decreased chemokine (CCL17 and CCL22) plasma levels at 2 weeks were associated with a subsequent response. The treatment was well tolerated, and the most common grade 3/4 AEs were neutropenia (47%), anemia (29%), and thrombocytopenia (18%). Four patients discontinued lenalidomide because of rash, elevated transaminases/bilirubin, and cytopenias. We provide preliminary evidence of lenalidomide's activity in patients with rel/ref cHL, and therefore exploration of lenalidomide in combination with other active agents is warranted. This trial is registered at www.ClinicalTrials.gov as NCT00540007." @default.
• W2017144533 created "2016-06-24" @default.
• W2017144533 creator A5003134947 @default.
• W2017144533 creator A5005446802 @default.
• W2017144533 creator A5015361329 @default.
• W2017144533 creator A5023116107 @default.
• W2017144533 creator A5027659475 @default.
• W2017144533 creator A5037428460 @default.
• W2017144533 creator A5041161932 @default.
• W2017144533 creator A5048989612 @default.
• W2017144533 creator A5056946123 @default.
• W2017144533 creator A5063153537 @default.
• W2017144533 creator A5065426246 @default.
• W2017144533 creator A5069393942 @default.
• W2017144533 creator A5082772492 @default.
• W2017144533 creator A5089882481 @default.
• W2017144533 date "2011-11-10" @default.
• W2017144533 modified "2023-10-05" @default.
• W2017144533 title "A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma" @default.
• W2017144533 cites W1495792176 @default.
• W2017144533 cites W1980068016 @default.
• W2017144533 cites W1988144615 @default.
• W2017144533 cites W2003600960 @default.
• W2017144533 cites W2007627691 @default.
• W2017144533 cites W2011118089 @default.
• W2017144533 cites W2034400622 @default.
• W2017144533 cites W2040994067 @default.
• W2017144533 cites W2097620275 @default.
• W2017144533 cites W2115695509 @default.
• W2017144533 cites W2116194748 @default.
• W2017144533 cites W2133201432 @default.
• W2017144533 cites W2136242714 @default.
• W2017144533 cites W2144531125 @default.
• W2017144533 cites W2153558008 @default.
• W2017144533 cites W2157575968 @default.
• W2017144533 cites W2159090549 @default.
• W2017144533 cites W2168937900 @default.
• W2017144533 cites W2172014713 @default.
• W2017144533 cites W2529676265 @default.
• W2017144533 cites W2557576962 @default.
• W2017144533 cites W2587995109 @default.
• W2017144533 cites W2979717982 @default.
• W2017144533 cites W2994047002 @default.
• W2017144533 doi "https://doi.org/10.1182/blood-2011-07-362475" @default.
• W2017144533 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3217400" @default.
• W2017144533 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21937701" @default.
• W2017144533 hasPublicationYear "2011" @default.
• W2017144533 type Work @default.
• W2017144533 sameAs 2017144533 @default.
• W2017144533 citedByCount "161" @default.
• W2017144533 countsByYear W20171445332012 @default.
• W2017144533 countsByYear W20171445332013 @default.
• W2017144533 countsByYear W20171445332014 @default.
• W2017144533 countsByYear W20171445332015 @default.
• W2017144533 countsByYear W20171445332016 @default.
• W2017144533 countsByYear W20171445332017 @default.
• W2017144533 countsByYear W20171445332018 @default.
• W2017144533 countsByYear W20171445332019 @default.
• W2017144533 countsByYear W20171445332020 @default.
• W2017144533 countsByYear W20171445332021 @default.
• W2017144533 countsByYear W20171445332022 @default.
• W2017144533 countsByYear W20171445332023 @default.
• W2017144533 crossrefType "journal-article" @default.
• W2017144533 hasAuthorship W2017144533A5003134947 @default.
• W2017144533 hasAuthorship W2017144533A5005446802 @default.
• W2017144533 hasAuthorship W2017144533A5015361329 @default.
• W2017144533 hasAuthorship W2017144533A5023116107 @default.
• W2017144533 hasAuthorship W2017144533A5027659475 @default.
• W2017144533 hasAuthorship W2017144533A5037428460 @default.
• W2017144533 hasAuthorship W2017144533A5041161932 @default.
• W2017144533 hasAuthorship W2017144533A5048989612 @default.
• W2017144533 hasAuthorship W2017144533A5056946123 @default.
• W2017144533 hasAuthorship W2017144533A5063153537 @default.
• W2017144533 hasAuthorship W2017144533A5065426246 @default.
• W2017144533 hasAuthorship W2017144533A5069393942 @default.
• W2017144533 hasAuthorship W2017144533A5082772492 @default.
• W2017144533 hasAuthorship W2017144533A5089882481 @default.
• W2017144533 hasBestOaLocation W20171445331 @default.
• W2017144533 hasConcept C126322002 @default.
• W2017144533 hasConcept C141071460 @default.
• W2017144533 hasConcept C143998085 @default.
• W2017144533 hasConcept C197934379 @default.
• W2017144533 hasConcept C2776063141 @default.
• W2017144533 hasConcept C2776364478 @default.
• W2017144533 hasConcept C2776694085 @default.
• W2017144533 hasConcept C2777063308 @default.
• W2017144533 hasConcept C2778248108 @default.
• W2017144533 hasConcept C2778570526 @default.
• W2017144533 hasConcept C2779050716 @default.
• W2017144533 hasConcept C2779338263 @default.
• W2017144533 hasConcept C2780653079 @default.
• W2017144533 hasConcept C2911091166 @default.
• W2017144533 hasConcept C31760486 @default.
• W2017144533 hasConcept C535046627 @default.
• W2017144533 hasConcept C71924100 @default.
• W2017144533 hasConcept C90924648 @default.
• W2017144533 hasConceptScore W2017144533C126322002 @default.
• W2017144533 hasConceptScore W2017144533C141071460 @default.

• next